Literature DB >> 23350965

Long-term outcome of small, organ-confined renal cell carcinoma (RCC) is not always favourable.

Tetsuya Shindo1, Naoya Masumori, Ko Kobayashi, Fumimasa Fukuta, Megumi Hirobe, Akiko Tonooka, Tadashi Hasegawa, Hiroshi Kitamura, Taiji Tsukamoto.   

Abstract

UNLABELLED: WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: Small, organ-confined renal cell carcinoma (RCC) generally has favourable pathological characteristics and a good prognosis. However, late recurrence is a known characteristic of the biological behaviour of RCC and no consensus has been established for surveillance protocols from 5 years after radical or partial nephrectomy. In the present study with long-term follow-up of patients with small RCCs, 18 of 172 patients (10.5%) with pT1a RCC developed recurrence and eight of these (4.7%) died from cancer. Patients with microvascular invasion had a higher risk for cancer death than those without (P < 0.001, Log-rank test). Therefore long-term follow-up is required after surgery, particularly when the disease has microvascular invasion.
OBJECTIVES: To identify the long-term clinical course of small, organ-confined renal cell carcinoma (RCC). To detect the risk factors of recurrence and of cancer death in small RCC. PATIENTS AND METHODS: Retrospectively reviewed 172 patients who were pathologically diagnosed as having pT1a RCC without metastasis at our institution from 1980 to 2005. All pathology slides were re-reviewed by a single experienced pathologist. Associations of microvascular invasion (MVI), development of metastasis, and cancer death were evaluated using Cox proportional hazards analysis.
RESULTS: During a median (range) follow-up of 104.5 (8-308) months, 18 patients (10.5%) developed progression and eight patients (4.7%) died from cancer. Kaplan-Meier curves showed higher cancer-specific survival (CSS) in patients without MVI (P < 0.001). In multivariate analysis, MVI was the only factor that reached statistical significance (P = 0.006). The 10-year CSS rates were 85.1% and 96.5% in patients with and without MVI, respectively.
CONCLUSIONS: Patients with MVI have worse survival than those without MVI. This suggests that long-term follow-up of patients with small RCCs is needed because of the risk of recurrence and cancer death even 10 years after surgery, particularly when the disease has apparent MVI.
© 2013 BJU International.

Entities:  

Mesh:

Year:  2013        PMID: 23350965     DOI: 10.1111/j.1464-410X.2012.11771.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

1.  Microvascular invasion as a prognostic indicator in renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Hai Huang; Xiu-Wu Pan; Yi Huang; Dan-Feng Xu; Xin-Gang Cui; Lin Li; Yi Hong; Lu Chen; Yi Gao; Lei Yin
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 2.  A clinical investigation of recurrence and lost follow-up after renal cell carcinoma surgery: a single-center, long-term, large cohort, retrospective study.

Authors:  Takayuki Arai; Tomokazu Sazuka; Hiroaki Sato; Mayuko Kato; Shuhei Kamada; Sota Katsura; Ayako Seito; Shu Miyamoto; Ken Wakai; Nobuyoshi Takeuchi; Yusuke Imamura; Shinichi Sakamoto; Akira Komiya; Tomohiko Ichikawa
Journal:  Int J Clin Oncol       Date:  2022-06-29       Impact factor: 3.850

3.  Renal Cell Carcinoma Presenting as Radiating Rib Pain: A 65-Year-Old Woman.

Authors:  Gregory Cofano; Meredith Meyers; Adam Sergent; Shawn LaCourt
Journal:  J Chiropr Med       Date:  2016-03-25

4.  Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis of cancer deaths occurring more than 10 years after initial treatment.

Authors:  Yuki Kyoda; Ko Kobayashi; Megumi Hirobe; Tetsuya Shindo; Fumimasa Fukuta; Kohei Hashimoto; Toshiaki Tanaka; Akiko Tonooka; Hiroshi Kitamura; Satoshi Takahashi; Naoya Masumori; Tadashi Hasegawa; Taiji Tsukamoto
Journal:  Int J Clin Oncol       Date:  2013-02-13       Impact factor: 3.402

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.